ArticleInvestigational new drugs2023

Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.

Yingying Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.